Commentary on Knight et al.: A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors.
Hay
J W
JW
Department of Clinical Pharmacy, Pharmaceutical Economics and Policy, University of Southern California, 1540 E Alcazar St, Los Angeles, CA 90089, USA. jhay@usc.edu
Zhou
Z-Y
ZY
D001779:Blood Coagulation Factors / Q000008:administration & dosage* / Q000191:economics; D003362:Cost-Benefit Analysis; D015942:Factor VIIa / Q000008:administration & dosage* / Q000191:economics; D006467:Hemophilia A / Q000188:drug therapy* / Q000191:economics; D006801:Humans; D008297:Male; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000191:economics; D012196:Review Literature as Topic
D001779:Blood Coagulation Factors; D011994:Recombinant Proteins; D015942:Factor VIIa